ALK and non-small cell lung carcinoma: EMT-driven NSCLC cross-resistance can be abrogated by silibinin, which directly inhibits TGFβR kinase activity and blocks the SMAD signaling cascade in mesenchymal ALK-rearranged NSCLC cells.